These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 19911355)

  • 1. Spironolactone therapy in heart failure patients with chronic kidney disease.
    Lopes R; Lourenco P; Mascarenhas J; Azevedo A; Bettencourt P
    Clin Cardiol; 2009 Oct; 32(10):597. PubMed ID: 19911355
    [No Abstract]   [Full Text] [Related]  

  • 2. Safety of spironolactone use in ambulatory heart failure patients.
    Kandula P; Shah R
    Clin Cardiol; 2009 Jun; 32(6):347-8. PubMed ID: 19569078
    [No Abstract]   [Full Text] [Related]  

  • 3. Life-threatening hyperkalemia: a complication of spironolactone for heart failure in a patient with renal insufficiency.
    Hu Y; Carpenter JP; Cheung AT
    Anesth Analg; 2002 Jul; 95(1):39-41, table of contents. PubMed ID: 12088939
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incidence, predictors, and outcomes related to hypo- and hyperkalemia in patients with severe heart failure treated with a mineralocorticoid receptor antagonist.
    Vardeny O; Claggett B; Anand I; Rossignol P; Desai AS; Zannad F; Pitt B; Solomon SD;
    Circ Heart Fail; 2014 Jul; 7(4):573-9. PubMed ID: 24812304
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety of spironolactone use in ambulatory heart failure patients.
    Lopes RJ; Lourenço AP; Mascarenhas J; Azevedo A; Bettencourt P
    Clin Cardiol; 2008 Nov; 31(11):509-13. PubMed ID: 19006114
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term effects of aldosterone blockade in resistant hypertension associated with chronic kidney disease.
    Pisoni R; Acelajado MC; Cartmill FR; Dudenbostel T; Dell'Italia LJ; Cofield SS; Oparil S; Calhoun DA
    J Hum Hypertens; 2012 Aug; 26(8):502-6. PubMed ID: 21677673
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Race influences the safety and efficacy of spironolactone in severe heart failure.
    Vardeny O; Cavallari LH; Claggett B; Desai AS; Anand I; Rossignol P; Zannad F; Pitt B; Solomon SD;
    Circ Heart Fail; 2013 Sep; 6(5):970-6. PubMed ID: 23940307
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Eplerenone and chronic heart failure. No comparison with spironolactone.
    Prescrire Int; 2013 Jun; 22(139):148-9. PubMed ID: 23866347
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hyperkalemia during spironolactone use in patients with decompensated heart failure.
    Lima MV; Ochiai ME; Cardoso JN; Morgado PC; Munhoz RT; Barretto AC
    Arq Bras Cardiol; 2008 Sep; 91(3):177-82, 194-9. PubMed ID: 18853060
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of an individualized dose titration regimen of patiromer to prevent hyperkalaemia in patients with heart failure and chronic kidney disease.
    Pitt B; Bushinsky DA; Kitzman DW; Ruschitzka F; Metra M; Filippatos G; Rossignol P; Du Mond C; Garza D; Berman L; Lainscak M;
    ESC Heart Fail; 2018 Jun; 5(3):257-266. PubMed ID: 29369537
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Spironolactone in chronic hemodialysis patients improves cardiac function.
    Taheri S; Mortazavi M; Shahidi S; Pourmoghadas A; Garakyaraghi M; Seirafian S; Eshaghian A; Ghassami M
    Saudi J Kidney Dis Transpl; 2009 May; 20(3):392-7. PubMed ID: 19414940
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hyperkalemia after the publication of RALES.
    Newsome BB; Warnock DG
    N Engl J Med; 2004 Dec; 351(23):2448-50; author reply 2448-50. PubMed ID: 15580678
    [No Abstract]   [Full Text] [Related]  

  • 13. Association of aldosterone concentration and mineralocorticoid receptor genotype with potassium response to spironolactone in patients with heart failure.
    Cavallari LH; Groo VL; Viana MA; Dai Y; Patel SR; Stamos TD
    Pharmacotherapy; 2010 Jan; 30(1):1-9. PubMed ID: 20030467
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incident Hyperkalemia, Hypokalemia, and Clinical Outcomes During Spironolactone Treatment of Heart Failure With Preserved Ejection Fraction: Analysis of the TOPCAT Trial.
    Desai AS; Liu J; Pfeffer MA; Claggett B; Fleg J; Lewis EF; McKinlay S; O'Meara E; Shah SJ; Sweitzer NK; Solomon S; Pitt B
    J Card Fail; 2018 May; 24(5):313-320. PubMed ID: 29572190
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure).
    Eschalier R; McMurray JJ; Swedberg K; van Veldhuisen DJ; Krum H; Pocock SJ; Shi H; Vincent J; Rossignol P; Zannad F; Pitt B;
    J Am Coll Cardiol; 2013 Oct; 62(17):1585-93. PubMed ID: 23810881
    [TBL] [Abstract][Full Text] [Related]  

  • 16. How prevalent is hyperkalemia and renal dysfunction during treatment with spironolactone in patients with congestive heart failure?
    Svensson M; Gustafsson F; Galatius S; Hildebrandt PR; Atar D
    J Card Fail; 2004 Aug; 10(4):297-303. PubMed ID: 15309695
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serious adverse events experienced by patients with chronic heart failure taking spironolactone.
    Berry C; McMurray JJ
    Heart; 2001 Apr; 85(4):E8. PubMed ID: 11250985
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Spironolactone-induced renal insufficiency and hyperkalemia in patients with heart failure.
    Tamirisa KP; Aaronson KD; Koelling TM
    Am Heart J; 2004 Dec; 148(6):971-8. PubMed ID: 15632880
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hyperkalemia in congestive heart failure patients aged 63 to 85 years with subclinical renal disease.
    Obialo CI; Ofili EO; Mirza T
    Am J Cardiol; 2002 Sep; 90(6):663-5. PubMed ID: 12231103
    [No Abstract]   [Full Text] [Related]  

  • 20. Hyperkalemia and Acute Kidney Injury with Spironolactone Use Among Patients with Heart Failure.
    Secora AM; Shin JI; Qiao Y; Alexander GC; Chang AR; Inker LA; Coresh J; Grams ME
    Mayo Clin Proc; 2020 Nov; 95(11):2408-2419. PubMed ID: 33153631
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.